ClinicalTrials.gg
RecruitingNCT06854679ANDROMEDAUpdated Mar 3, 2025

Dose Escalated Radiotherapy for Rectal Cancers Using MR-guided Radiotherapy

An interventional study of Radiotherapy dose escalation in Rectal Adenocarcinoma, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by Royal Marsden NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Rectal Neoplasms by Royal Marsden NHS Foundation Trust — 2 open to participants now, 2 under way, none of them phase 3. Rectal Neoplasms · Royal Marsden NHS Foundation Trust.

Started
2025
the only one that year
No phase
4 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Rectal Neoplasms by Royal Marsden NHS Foundation Trust, this one is the only one that started in 2025, is one of 4 with no phase, and was the 15th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

2 of the 15 studies in Rectal Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Rectal Neoplasms by Royal Marsden NHS Foundation Trust, or all of them as a file.
02

Study summary

Standard radiotherapy in the UK involves having daily chemotherapy tablets with radiotherapy treatment for 5 weeks at a dose of 52.5Gy to the rectal cancer over 25 fractions. This is the likely treatment participants will be having if they decide not to take part in this study. Increasing the dose to 60Gy is shown to increase the chance that rectal cancer will be treated completely, a term known as "complete pathological response". Patients who have a complete pathological response after their treatment can avoid surgery and enter into a surveillance programme to monitor for early signs of the cancer returning. Surveillance can mean 3-6 months camera tests and MRI scans depending on the local unit. If these patients continue to show signs of complete pathological response then they can avoid long term complications from surgery such as a stoma. Unit studies have shown that that increasing the dose of radiotherapy can cause slightly more bowel and bladder side effects, but using adaptive radiotherapy to limit radiotherapy to normal tissue could keep the rate of bothersome side effects as low, which is similar as standard treatment.

All adaptive treatments within this trial will be delivered on a state of the art, radiotherapy machine called an MR-linac (Magnetic Resonance Linear Accelerator). It combines an MRI scanner with a radiotherapy treatment machine called a Linear Accelerator (called a 'linac' for short). The use of the MR-linac means there is no extra radiation dose given when taking daily images to check for the position of participants rectal cancer (unlike CT scans or X-ray). It also enables the investigators to adapt or 'tweak' the radiotherapy plan each day to match the exact position of the rectal cancer and adjacent organs. The non-adaptive fractions can be delivered on either the MR-Linac or CT-linac depending on factors such as treatment machine availability.

The investigators will deliver the treatment on the MR-linac using a technique called intensity modulated radiotherapy (precise X-ray treatment, called IMRT for short). IMRT is able to mould radiotherapy treatment according to what the investigators can see, therefore enabling the investigators to give highly targeted treatment. The investigators already have considerable experience in delivering radiotherapy to rectal cancer with this machine and now wish to focus on whether they could increase dose to benefit long term outcome for all rectal cancer patients as well as reducing the side effects of treatment.

The purpose of this research is to increase the dose to rectal cancer while adapting to the changes that the investigators can see to the rectal cancer during treatment. This means that if the rectal cancer is seen to reduce in size they will be able to deliver a 'shrinking boost' according to what can be seen. This will enable the investigators to give high dose radiotherapy to the cancer whilst limiting radiotherapy to healthy tissue. Without the ability to adapt to changes that the investigators see to the tumour throughout the entire treatment course, standard treatment delivers dose to a larger area of surrounding healthy tissue to ensure that the tumour is sufficiently targeted.

The investigators want to find out if by using this adaptive, shrinking boost approach, they can safely increase radiotherapy dose to rectal cancer, whilst limiting the side effects you experience, in comparison with standard treatment. If this is possible, then this would lead into further clinical trial where the investigators would compare outcomes of higher-dose treatment to standard-of-care. The investigators can't be certain that the side effects will be different, and they don't know if this treatment results in the best chance of cancer cure. However they know from other studies that this is the likely outcome, with surgery being delayed for patients. Patients who have a complete pathological response after combined chemotherapy and radiotherapy treatment enter into a surveillance programme where MRI and camera tests (flexible sigmoidoscopy) are performed at regular intervals looking for early signs of cancer returning.

The investigators expect that the chance of participants having a complete pathological response with this technique is higher than with standard dose, although the investigators can't know this for sure until they have completed further studies. It is possible that the cure rate may be lower or higher than the standard dose.

03

Conditions studied

  • Rectal Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients aged ≥18 years
  • Histological confirmation of locally advanced rectal adenocarcinoma requiring chemoradiotherapy as per RMH clinical guidelines.
  • Patients suitable for concomitant chemotherapy
  • Patients with disease included within treatment field size of MR-Linac.
  • 0-2
  • Ability of the participant understand and the willingness to sign a written form.
  • Ability/willingness to comply with the patient reported outcome questionnaires schedule throughout the study.

Exclusion criteria

Exclusion Criteria:

  • to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)
  • Disease outside maximum radiotherapy treatment field length.
  • Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up
  • Unilateral or bilateral total hip replacement, or other pelvic metalwork which causes artefact on diffusion-weighted imaging
  • Previous pelvic radiotherapy
  • Patients needing induction chemotherapy prior to chemoradiotherapy
  • Previous invasive within the last 2 years excluding basal or squamous cell carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    Radiotherapy dose escalation

    All patients will receive 45Gy in 25# to mesorectum and elective nodal volumes, and 52.5Gy in 25# as standard to primary gross tumour volume which includes primary tumour, visible nodal disease and extramural vascular invasion if present. Boost dose escalation to a maximum of 60Gy will be delivered to patients with ongoing visible disease from week 2 of treatment onwards.

    Radiation: Radiotherapy dose escalation

Interventions

  • RadiationRadiotherapy dose escalation

    All patients will receive 45Gy in 25# to mesorectum and elective nodal volumes, and 52.5Gy in 25# as standard to primary gross tumour volume which includes primary tumour, visible nodal disease and extramural vascular invasion if present. Boost dose escalation to a maximum of 60Gy will be delivered to patients with ongoing visible disease from week 2 of treatment onwards.

06

What researchers measure

Primary outcomes

  1. Number of patients completing 90% or more fractions delivered on MR-Linac.

    To establish the technical feasibility of delivering adaptive dose escalated radiotherapy on an MR-Linac.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. • Physician reported gastrointestinal (GI) and genitourinary (GU) toxicity (CTCAE grade) at baseline and the end of treatment then at 6 and 12 weeks post-treatment.

    • Physician reported gastrointestinal (GI) and genitourinary (GU) toxicity (CTCAE grade) at baseline and the end of treatment then at 6 and 12 weeks post-treatment.

    Time frame: 24 months post completing treatment

  2. • Late toxicity (CTCAE) at 1 and 2 years post-treatment.

    • Late toxicity (CTCAE) at 1 and 2 years post-treatment.

    Time frame: 24 months post completing treatment

  3. • Recurrence/progression assessment for up to 2 years following completion of treatment.

    • Recurrence/progression assessment for up to 2 years following completion of treatment.

    Time frame: 24 months post completing treatment

  4. • Post-treatment pathological response assessment at 6 weeks with MRI using Mandard response grading. If complete pathological response on MRI then patient will undergo surgical surveillance with sigmoidoscopy and biopsy. If ongoing disease patient will

    • Post-treatment pathological response assessment at 6 weeks with MRI using Mandard response grading. If complete pathological response on MRI then patient will undergo surgical surveillance with sigmoidoscopy and biopsy. If ongoing disease patient will have appropriate surgical technique for removal of tumour.

    Time frame: 24 months post completing treatment

  5. • Patient-reported outcome measures (PROMs)

    Patient-reported outcome measures (PROMs) from the QLQ-CR29 and QLQ-C30 questionnaires. Patients will be asked to complete PROMs at 6 and 12 weeks, 6 months, 1 and 2 years post treatment. Scale of 1(low impact) to 4 (high impact)

    Time frame: 24 months post completing treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 22 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Mar 3, 2025
StartActual
Feb 14, 2025
Primary completionEst.
Jan 13, 2027
CompletionEst.
Jan 13, 2029
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06854679
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Feb 14, 2025
Primary completion
Jan 13, 2027 (estimated)
Completion
Jan 13, 2029 (estimated)
Last update
Mar 3, 2025

Study contacts

Brian Hin, FRCR MD(res)
Contact
brian.hin@rmh.nhs.uk
extension 4228

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion